A Potential Imaging Agent for SPECT Investigations of Benzodiazepine Receptors

Total Page:16

File Type:pdf, Size:1020Kb

A Potential Imaging Agent for SPECT Investigations of Benzodiazepine Receptors Radioiodinated 2'-.Iododiazepam: A Potential Imaging Agent for SPECT Investigations of Benzodiazepine Receptors Hideo Saji, Yasuhiko lida, Iwao Nakatsuka, Masaki Kataoka, Kazuhiko Ariyoshi, Yasuhiro Magata, Akira Yoshitake and Akira Yokoyama Faculty ofPharmaceutical Sciences, Kyoto Unwersisy, Kyoto, Japan and Environmental Health Science Laboratoiy, Swnitomo Chemical Company Ltd., Osaka@Japan relationshipshave shown that substitution with electron 2'-lododiazepam (2'-IDZ)isthe diazepam analogue iodinatedat withdrawinggroups such as halogens at position 7 and 2' the 2'-posilionof C-5 phen@1nngwh@hwas synthesizedand increases receptor affinity (2,17,18). lodination at position evaluated as a potential radiopharrnaceuticalfor invesligaling 7 yields 7-iodo-flunitrazepam, and the synthesis and bio brain benzodiazepine receptors by SPECT. The 1@l-2'-iododi distribution of this agent have been recently reported (13). azepam was SyntheniZedby halogen exchange reacOonand In this study, a diazepam derivative iodinated at the 2' pu@fledby HPLC.In vitrocompetitivebindingstudieswith3H- position, 2'-iododiazepam (2'-IDZ), was synthesized and diazepam,using rat cor@calsynaptosomalmembranes,showed the in vitro receptor binding affinityand biodistributionin that the affinity of 2'-IDZ for benzodiazepam receptors was higherthanthatin diazepamandflumazenil(R015-1788).Blo mice, including regional cerebral distribution, were stud distnbution studies in mice showed that the brain uptake of ied. The chemical structures of 2'-IDZ and related com 2'-iododiazepamwas rapidand profound,and inthe brainhigher pounds are shown in Figure 1. accumulationwas found in the cortexthan in other regions. Furthermore,the cortical uptake was displaced by benzodiaz MATERIALS AND METhODS epinergiccompounds.Invivouptakewasassessedby autora Sodium‘@I-iodide(specificactivity 81.4TBq/mmole)and 3H- diographicstudies.Thus, 2'-iododiazepamboundto benzoduaz diazepam (3.15 Thq/mmole) were purchased from Amersham In epine receptorsin vivo and therefore holds great potentialfor in temational Plc and Du Pont New England Research Products, v@,obenzodiazepinereceptorstudies. respectively.Diazepamand flumazenil(R015-1788)were a gen J NuciMed1993;34:932-937 erousgiftfromF. Hoffmann-LaRoche(Basel,Switzerland).Flu diazepamwas suppliedby SumitomoChemicalCo. Ltd. (Osaka, Japan).MaleWistarratsandddYmicewere suppliedby Japan SIC Co. Ltd. (Hamamatsu, Japan). enzodiazepines induce various pharmacological ef Radlolabellng fects which are thoughtto be mediatedvia benzodiazepine The radioiodinationof 2'-IDZwas accomplishedby halogen receptors in the central nervous system (1,2). Alterations in exchangereactionwith sodium‘@I-iodide.Eighty-fivemicro thedensityofbenzodiazepinereceptorshaverecentlybeen gramsof 2'-bromodiazepam(BDZ)was dissolvedin 107 @.ddim ethylformamide(DMF).Thissolutionwas addedto a mixtureof reportedin various disorders, such as epilepsy (3,4), Hun sodium‘@I-iodide(10 @d,37MBq),nonradioactivesodiumiodide tington's disease (5,6), hepatic encephalopathy (7) and Alz (0.8 @tgin0.25 @d0.1N NaOH),1-naphthalenesulfonicaciddihy heimer's disease (8). Visualization of benzodiazepine re drate(0.26 mg in 5 @lDMF) and copper (II) sulfate pentahydrate ceptorsin humanbrain hasthusbeenof greatinterest, and (0.26mgin 5 pi DMF) in a sealedvial. The reactionmixture was several “C-,75Br-, and ‘@I-labeledbenzodiazepines have heatedfor 1.5 hr at 100—105°C.Aftercooling,400 @lof 10% been developed for this purpose (9—16).The successful aqueoussodiumcarbonatesolutionwas addedto the reaction imaging of benzodiazepine receptors with these radiola mixture and the product was extracted with chloroform (2 x 0.5 beled compoundsand the superior radiation propertiesof ml).Thecombinedorganiclayerswereevaporatedunderastream ‘@Ifor SPEC!' promptedus to synthesize a radioiodinated ofnitrogen. The residue was dissolved in 100—150p1 of methanol, benzodiazepine analogue with high receptor affinity. applied to a reverse-phase, high-performance liquid chromatogra In the 1,4-benzodiazepine molecule, structure-activity phy (HPLC)column(LichrosorbRP-18,7.5 x 300 mm), and elutedwithmethanol:water:4-mMphosphatebuffer(pH7.4)(11: 5:4)at a flowrateof 1.5mi/rain(R@= 58miiifor 2'-BDZ, R@= 62 mmfor2'-IDZ).The fractioncorrespondingto 2'-IDZwas col ReceivedSept 10, 1992;revisionacceptedFeb.8, 1993. lected, evaporated to remove the residual organic solvent and Forcorrespondenceorreprintscon@ frJdraYokoya@PhD,Departmentof Raclopharmaceudcalchem@by,Facultyof PhaimaceuticalSdences, KyoloUrn sterilized by ifitration through a 0.22 pin Milex ifiter. @rernily,YoehklaSl*noadachi-cho,Sakyo.ku,Kyolo606-01,Japan. The radiochemicalpurityof the productwas determinedby 932 TheJournalofNudearMedicine•Vol.34•No.6•June1993 3H-diazepambindingversusinhibitor concentrationandwere the average of three to five experiments. MeasurementoftheOctanol/WaterPartitionCoefficient Thepartitioncoefficientfor2'-IDZwas determinedaccording to apreviouslyreportedmethod(21).A 20-idaliquotof radioio Cl dinated sample was mixed with 3 ml each of 1-octanol and 0.1 M phosphatebuffer(pH7.4)in a testtube.Thetubewasvortexed (3x 1 mm),incubatedfor 1 hr at roomtemperature,and then centrifugedfor 5 mm. The 5OO-@daliquots of each phase were removed and counted in a well-type Na! scintillation counter. CompoundRDiazepamHFludiazepamF2'-IDZI Blodlstrlbutlon StudIes Male ddY mice weighing about 30 g were administered ‘@I-2'- IDZ(18.5kBqin 0.1mlethanolicsalinesolution)throughthe tail vein. At thedesignatedtimesaftertheinjections,themicewere FIGURE1. chemIcalstruc turesof2'-IDZandrelatedcorn killed by decapitation and their organs were removed. For in vivo brain disthl,ution studies, the brains were dissected on an ice-cold plateaccordingto themethodof GlowinskiandIversen(22).All sampleswereweighed,andthe radioactivitywascountedusinga thin-layer chromatography (TLC) and analytical HPLC. The TLC well-typeNa! scintillationcounter.Resultswere presentedas the wasperformedonasilicagelplatewithachloroform:acetone(4:1) %dose/gtissueweight. solvent (R@= 0.62-0.68). HPLC was performed on a 7.5 x 300 Therelativebindingaffinityof ‘@I-2'-mZfor the benzodiaz mm Lichrosorb RP-18columnelutedwith methanokwater:4-mM epinereceptorwas determinedby usingknownagonistsandan phosphate buffer (pH 7.4) (11:5:4) at a flow rate of 1.5 mI/mm tagothsts with high affinity, which were injected into mice along (R1 = 62 mm). with 18.5 kBq of 1@I-2'-mZ. Flumazenil (1.0 mgfkg)was injected The nonradioactive 2'-IDZ and 2'-BDZ were synthesized from simultaneouslywiththe radioligand,but diazepam(10m@Jkg)and 2-iodo- or 2-bromobenzoic acid by addition of N-(4-chlorophe flunitrazepam (10 mg/kg) were injected intraperitoneally 30 min nyl)-N-methylethylenediamine, followed by cydlization and oxi before administration of the radioligand. The animals were sacri dation, according to the method previously reportedfor the cor ficed 1, 5, 20 and 60 mm after radioligandadministration,brain respondingfluoroanalogue,fludiazepam(19).Thestructureswere regionswere dissected,andtissueswere countedas described confirmed by infrared analysis (IR), proton nuclear magnetic res above.Theeffectof sodiumthiopentalon ‘@I-2'-mZuptakewas onance(NMR)andmassspectrometricanalysis.The detailsof also studied. Mice were injected intraperitoneally with sodium the synthesisandcharacterizationof these compoundswill be thiopental(100mg/kg)10 mm before radioligandadministration publishedelsewhere. andtreatedinthesamemanneras describedabove. To demonstratereceptorsaturation,18.5kBq of ‘@I-2'-mZ In Vitro BenzodlazeplneReceptorBIndIngStudIes was coinjectedwithvariousdoses of cold 2'-IDZ,rangingfrom The affinity of 2'-IDZ for benzodiazepine receptors was mea 0.01to 1.0mgfkg.Theanimalswere killed5 mmafterinjection sured by displacement of 3H-diazepam from a preparationof andthebrainsweredissectedandcountedas describedabove. synaptosomal membranes, according to the method of MOhler andOkada(20).Inbrief,thecerebralcortexfrommaleWistarrats Metabollsm (150-200g) was homogenizedin 20volumesof ice-cold0.32M Mice weighing about 30gwere injected intravenouslywith 55.5 sucrose using a Teflon-glass homogeneizer. The homogenate was kBq of 1@I-2'-IDZ.At designated times afterward, the mice were centrifuged at 1,000x g for 10 mm at 4°C.The supernatant was decapitated,and the brains were removedimmediatelyand ho recentrifuged at 20,000x g for 20 mm at 4°C. The pellet was mogenized in 1 ml of methanol. After centrifugation, the precipi resuspended in ice-cold 50 mM Krebs-Tris buffer (50 mM Tris tatewaswashedtwicewith 1 ml of methanol,andthewashes HQ buffer(pH7.4),118mMNaG, 4.8mMK@, 1.2mMCaCl2, were combined with the supernatant. The combined methanol 1.2 mM MgCl2)with polytron homogenizer, and dilutedwith the extracts were evaporated, and the resultingresidue was redis Krebs-Ths bufferto yield a synaptosomalmembranesuspension solved in a small volume of methanol and analyzed by HPLC on witha proteinconcentrationof 1.0mgprotein/mt. aLichrosorbP2-18column(7.5x 300mm)withmethanokwater: The bindingassays were performedby incubating1 ml of the 4-mM phosphate buffer (pH 7.4) (11:5:4) at a flow rate of 1.5 synaptosomal membrane suspension with 3H-diazepam (0.6 nM) mi/mm. anddifferentconcentrationsof competitorsin 1mlof Krebs-Tris buffer.Incubationswere performedfor 15 mmat 4°C,andthe AutoradlographicStudies sampleswere rapidly filtered througha WhatmanOF/B filter and Twogroupsofrats weighingabout250gwereused. Onegroup washedtwicewith5 ml of ice-coldassaybuffer.The
Recommended publications
  • Analysis of a Benzodiazepine-Based Drug Using GC-MS 28
    LAAN-E-MS-E028 GCMS Gas Chromatograph Mass Spectrometer Analysis of a Benzodiazepine-Based Drug Using GC-MS 28 Benzodiazepine drugs are commonly used in sleeping aids and tranquilizers, and sometimes in crimes or suicide. Therefore, these chemical substances are often analyzed by forensic laboratories for criminal or academic investigations. This datasheet shows the results from using GC-MS to measure 9 types of benzodiazepine drugs. Analysis Conditions Table 1: Analysis Conditions GC-MS :GCMS-QP2010 Ultra Column : Rxi®-5Sil MS (30 mL. X 0.25 mmI.D., df=0.25 µm, Shimadzu GLC P/N:13623) Glass insert :Silanized splitless insert (P/N: 221-48876-03) [GC] [MS] Vaporization chamber temperature : 260℃ Interface temperature : 280℃ Column oven temperature : 60℃ (2min) -> (10℃/min) -> 320℃ (10min) Ion source temperature : 200℃ Injection mode : Splitless Solvent elution time : 2.0 min Sampling time : 1 min Measurement mode : Scan High pressure injection method: 250 kPa (1.5 min) Mass range : m/z 35-600 Carrier gas : Helium Event time : 0.3 sec Control mode :Linear velocity (45.6 cm/sec) Emission current : 150 µA (high sensitivity) Purge flow rate :3.0 ml/min Sample injection quantity :1.0 µL (x1,000,000) 3.0 3 2.5 2 2.0 1.5 1.0 1 0.5 22.0 23.0 24.0 25.0 26.0 27.0 28.0 min % % 312 55 100.0 1 285 100.0 2 313 109 75.0 75.0 266 259287 342 166 50.0 238 50.0 248 25.0 183 25.0 63 109 0.0 0.0 100 200 300 400 100 200 300 400 % 86 100.0 3 75.0 50.0 25.0 58 99 183 315 387 0.0 100 200 300 400 Fig.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • 124.210 Schedule IV — Substances Included. 1
    1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital).
    [Show full text]
  • S1 Table. List of Medications Analyzed in Present Study Drug
    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
    [Show full text]
  • Report on the Investigation Results
    Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. Report on the Investigation Results February 28, 2017 Pharmaceuticals and Medical Devices Agency I. Overview of Product [Non-proprietary name] See Attachment 1 [Brand name] See Attachment 1 [Approval holder] See Attachment 1 [Indications] See Attachment 1 [Dosage and administration] See Attachment 1 [Investigating office] Office of Safety II 1 Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. II. Background of the investigation 1. Status in Japan Hypnotics and anxiolytics are prescribed by various specialties and widely used in clinical practice. In particular, benzodiazepine (BZ) receptor agonists, which act on BZ receptors, bind to gamma-aminobutyric acid (GABA)A-BZ receptor complex and enhance the function of GABAA receptors. This promotes neurotransmission of inhibitory systems and demonstrates hypnotic/sedative effects, anxiolytic effects, muscle relaxant effects, and antispasmodic effects. Since the approval of chlordiazepoxide in March 1961, many BZ receptor agonists have been approved as hypnotics and anxiolytics. Currently, hypnotics and anxiolytics are causative agents of drug-related disorders such as drug dependence in Japanese clinical practice. Hypnotics and anxiolitics that rank high in causative agents are BZ receptor agonists for which high frequencies of high doses and multidrug prescriptions have been reported (Japanese Journal of Clinical Psychopharmacology 2013; 16(6): 803-812, Modern Physician 2014; 34(6): 653-656, etc.).
    [Show full text]
  • A Review of the Evidence of Use and Harms of Novel Benzodiazepines
    ACMD Advisory Council on the Misuse of Drugs Novel Benzodiazepines A review of the evidence of use and harms of Novel Benzodiazepines April 2020 1 Contents 1. Introduction ................................................................................................................................. 4 2. Legal control of benzodiazepines .......................................................................................... 4 3. Benzodiazepine chemistry and pharmacology .................................................................. 6 4. Benzodiazepine misuse............................................................................................................ 7 Benzodiazepine use with opioids ................................................................................................... 9 Social harms of benzodiazepine use .......................................................................................... 10 Suicide ............................................................................................................................................. 11 5. Prevalence and harm summaries of Novel Benzodiazepines ...................................... 11 1. Flualprazolam ......................................................................................................................... 11 2. Norfludiazepam ....................................................................................................................... 13 3. Flunitrazolam ..........................................................................................................................
    [Show full text]
  • II.3.4 Benzodiazepines by Hiroshi Seno and Hideki Hattori
    3.4 II.3.4 Benzodiazepines by Hiroshi Seno and Hideki Hattori Introduction Benzodiazepines show antianxiety, hypnotic, anticonvulsant and muscle-relaxant eff ects. Th is group of drugs has wide safety dose ranges; it means that the ratio of the LD50 to the ED50 (therapeutic index) is high. Because of its safety, benzodiazepines are being widely used in the world. Some of benzodiazepines are also being abused or used for so-called “ drug facilitated sexual assault”, and thus they are under the control of the Narcotics and Psychotropics Control Law; in Japan, triazolam abuse has become one of the serious social problems. In this chapter, a GC/MS method for simultaneous analysis of 22 kinds of benzodiazepines listed in > Table 4.1 is described. In addition, the LC/MS analysis of triazolam, and its metabolites 4-hydroxy- triazolam and α-hydroxytriazolam is also presented. GC/MS analysis of benzodiazepines in blood and urine Reagents and their preparation • Th e pure powder of the 22 kinds of benzodiazepines was donated by each pharmaceutical manufacturers according to the authors’ request a (some of benzodiazepines now obtaina- ble from Sigma, St. Louis, MO, USA). • 1 M Sodium bicarbonate solution: a 8.4-g aliquot of sodium bicarbonate is dissolved in distilled water to prepare 100 mL solution. • 2 M Sodium acetate solution: a 27.5-g aliquot of sodium acetate is dissolved in distilled water to prepare 100 mL solution. GC/MS conditions Column: a DB-5 fused silica capillary column (30 m × 0.25 mm i.d., fi lm thickness 0.25 µm, J & W Scientifi c, Folsom, CA, USA).
    [Show full text]
  • PMDA Alert for Proper Use of Drugs When Using Benzodiazepine
    ■ PMDA Alert for Proper Use of Drugs https://www.pmda.go.jp/english/safety/info-services/drugs/properly- No. 11 March 2017 use-alert/0001.html PMDA Alert for Proper Use of Drugs Pharmaceuticals and Medical Devices Agency No. 11 March 2017 Dependence associated with Benzodiazepine Receptor Agonists [To Patients] This document is for healthcare professionals. If taking the drug, please consult with your physicians or pharmacists. Please don’t reduce the dosage or stop taking the drug on self-judgment. Benzodiazepine receptor agonists have a characteristic of developing physical dependence with long-term use even within an approved dose range, leading to various withdrawal symptoms on dose reduction or discontinuation. <Major withdrawal symptoms> insomnia, anxiety, feeling irritated, headache, queasy/vomiting, delirium, tremor, seizure, etc. Please pay careful attention to the following when using benzodiazepine receptor agonists as hypnotics-sedatives and anxiolytics. Healthcare professionals should avoid long-term use with chronic administration. - Dependence may occur with long-term use even within an approved dose range. - Therapeutic necessity should be carefully considered when continuing administration of the drug. Healthcare professionals should adhere to the dosage and confirm that there is no multiple prescription of similar drugs. - Long-term administration, high-dose administration, or multiple medications increase the risk of developing dependence. - Healthcare professionals should confirm that similar drugs are not prescribed by other medical institutions. Healthcare professionals should reduce the dose or discontinue carefully such as by gradual dose reduction or alternate-days administration when discontinuing the administration. - Sudden discontinuation will develop serious withdrawal symptoms in addition to aggravate primary diseases.
    [Show full text]
  • Use and Abuse of Benzodiazepines*
    A rticles in the Update series Les articles de la rubrique give a concise, authoritative. Le point fournissent un and up-to-date wurvev of the bhilan concis et fiable de la present position in the se- I .ituation actuelle dans le lected fields, and, over a domaine considere. Des ex- ,/t a e period of years, will cover perts couvriront ainsi .vucl- man v different aspe ts of cessivement de nombreux the biomedical sciences aspects des sciences bio- L e p ointt atid public health. .Mo.st oJf mdicales et de la sante the articles will be writ- publique. La plupart de ces ten, by invitation. bv ic- articles auront donc ete A/nowledged experts on the rediges stir demande par les subject. specialistes les plus autorises. Bulletin ofthe World Health Organization, 61 (4): 551 - 562 (1983) © World Health Organization 1983 Use and abuse of benzodiazepines* WHO REVIEW GROUP Benzodiazepines are widely used for the treatment of anxiety, insomnia, and certain neuromuscular and convulsive disorders. However, their widespread avail- ability has given rise to fears that they are over-prescribed. The problem is compounded by the fact that there is no universal agreement among medical prac- titioners as to the clinical indications warranting the use of these drugs. Although most industrialized countries exercise control over the sale and manufacture of benzodiazepines, many developing countries do not have sufficient control of these drugs. As a result, information on drug utilization and associated problems is diffi- cult to obtain and there is a lack ofcomparative data on drug consumption in differ- ent countries.
    [Show full text]
  • Prescription & Illicit Drug Certified Reference Materials
    Prescription & Illicit Drug Certified Reference Materials Many analgesics clinically prescribed to manage chronic pain carry warranted concerns over safety and abuse liability. Further complications can arise from drug-drug interactions when stimulants or other illicit compounds are also abused. Cayman Chemical offers Certified Reference Materials (CRMs) to help identify, confirm, and quantify many of the major opioids, benzodiazepines, psychoactive drugs, and other controlled substances. Our CRMs meet ISO/IEC 17025 and ISO 17034 standards and are sold as quantitative solutions in sealed ampules. Opioid CRMs Benzodiazepine CRMs Item No. Product Name Item No. Product Name ISO60128 Acetyl fentanyl (hydrochloride) (CRM) ISO60185 Alprazolam (CRM) 23060 Acrylfentanyl (hydrochloride) (CRM) ISO60181 Clonazepam (CRM) 25936 Benzyl fentanyl (hydrochloride) (CRM) 25614 Clonazolam (CRM) ISO60178 Buprenorphine (hydrochloride) (CRM) ISO60177 Diazepam (CRM) 19734 Butyryl fentanyl (hydrochloride) (CRM) 28623 Diclazepam (CRM) 19884 Carfentanil (CRM) 20991 Etizolam (CRM) 26637 Crotonyl fentanyl (CRM) 25577 Flualprazolam (CRM) 23603 Cyclopropyl fentanyl (hydrochloride) (CRM) 26352 Flubromazolam (CRM) ISO60197 Fentanyl (hydrochloride) (CRM) 18160 Flurazepam (CRM) 25615 β-methyl Fentanyl (hydrochloride) (CRM) 19391 Midazolam (CRM) 19795 FIBF (hydrochloride) (CRM) 19206 Nimetazepam (CRM) 19826 para-Fluorobutyryl fentanyl (hydrochloride) (CRM) ISO60172 Phenazepam (CRM) 19633 Furanyl fentanyl (hydrochloride) (CRM) ISO60182 Temazepam (CRM) ISO60187 Heroin (CRM)
    [Show full text]
  • 疑似fludiazepam 引起EPS
    Therapeutics of Clinical Drugs 臨 床 藥 物 治 療 學 疑似 Fludiazepam 引起 EPS 症候群 中山醫學大學附設醫院藥劑科藥師 廖文聰、蕭如君 中山醫學大學醫學系兼任講師 蔡敏鈴 摘要 Fludiazepam (Erispan ) 是屬於 benzodiazepine 類的抗焦慮劑,臨床上常用來作為 患者焦慮狀態、失眠、肌肉痙攣狀況之解除,常見的副作用為嗜睡、頭暈目眩、倦 怠感⋯等。本案例描述一位42歲女性患者服用了過量的 fludiazepam 隔日即出現錐體 外徑症候群 (extrapyramidal syndromes; EPS) 症狀中的肌張力不全 (dystonia),在給予 biperiden 5 mg 靜脈輸注約3小時後,患者症狀才得以解除。Benzodiazepine 類藥品可 做為 EPS 症狀中肌肉痙攣狀況的治療,至於服用此類藥品後反而產生 EPS 的狀況實 屬罕見,因此藉由文獻的蒐尋相關的證據來探討其中的相關性以便能夠更安全的使用 fludiazepam 類藥品。 關鍵字: Erispan、EPS、dystonia、benzodiazepine、biperiden 壹、前言 二、 巴金森氏症效應 (Parkinsonian Benzodiazepine 類藥品常用在焦慮症狀 syndrome) 的解除,在建議劑量下使用應是有效而安全 靜止時顫抖 (resting tremor),單邊或雙 的,但若遭濫用而產生藥品的 ADR 卻是用 邊的手臂或雙腿、雙腳、下巴會不由自主地 藥安全上的一大隱憂。 抖動。肌肉僵直 (rigidity)、肢體僵硬、動作 而錐體外徑症候群常見的臨床症狀如 遲緩、講話速度緩慢、音調呆板、臉部表情 下:若是由藥品引起的 EPS 在初期最常見的 僵硬 (poker face 撲克臉)、眨眼頻率變少。 症狀是肌張力異常,而遲發性的運動困難則 姿勢保持反射障礙 (postural instability),出 見於長期使用藥品的患者身上。 現前傾姿勢、小碎步、走路時向前衝等狀 態。 一、靜坐不能 (Akathisia) 三、肌張力異常 是 EPS 最常見的症狀。患者有坐不 (Dystonias) 住、無法克制想起來走動的感覺,不斷交換 此症狀常見於年輕患者,患者的肌肉群 坐與站的姿勢,或是即使站在定點腳也不停 會不自主收縮進而造成特殊的姿勢,斜頸是 地踏步。 其特點,另有角弓反張、眼球上吊、舌外伸 第28卷第4期 藥學雜誌 第113冊 Dec. 31 2012 101 臨 床 藥 物 治 療 學 Therapeutics of Clinical Drugs 或捲曲、嘴巴歪斜、喉部痙攣甚至可能危及 相 關 文 章 , 搜 尋 到 的 文 章 反 而 建 議 可 用 生命。 benzodiazepine 類的藥品作為 EPS 症狀的輔 助療法。不過另外卻也搜尋到幾篇 diazepam 四、 遲 發 性 運 動 困 難 ( T r a d i v e 引起 dystonia 的文章,例如 Edmond A. dyskinesia) Hooker, and Daniel F. Danzl, 在1988年發表了 常發生在抗精神病藥品使用六個月以上 acute dystonic reaction due to diazepam 一文, 或數年後,臉的下半部和四肢末端會發生一 其中提到兩個因服用 diazepam 而引起斜頸 些非自主性的運動,如:唇動、舌頭經常往 等 dystonia 症狀的案例,且其中一例經抽血 外突且下垂、扮鬼臉及手部顫抖等動作。 作毒理學分析 (toxicologic analysis)
    [Show full text]
  • Appendix 1 Cross-Reference of Research, Generic and Trade Names of Benzodiazepines
    Appendix 1 Cross-Reference of Research, Generic and Trade Names of Benzodiazepines Table 1. Benzodiazepine research designations with corresponding generic names Research Designation Generic Name lactam demoxepam methyloxazepam temazepam A 101 nordazepam AB 35616 clorazepate AB 39083 clorazepate AH 3232 clorazepate CB 4261 tetrazepam CB 4306 clorazepate CB 4311 clorazepate CGS 8216 (antagonist) CI683 ripazepam CS 370 cloxazolam CS 430 haloxazolam D40TA estazolam EGYT 341 tofisopam ER 115 temazepam HR 158 loprazolam HR376 clobazam HR 4723 clobazam HR930 fosazepam K3917 temazepam 287 THE BENZODIAZEPINES Research Designation Generic Name LA 111 diazepam LM 2717 clobazam ORF 8063 triflubazam Ro 4-5360 nitrazepam Ro 5-0690 chlordiazepoxide Ro 5-0883 desmethy1chlordiazepoxide Ro 5-2092 demoxepam Ro 5-2180 desmethyldiazepam Ro 5-2807 diazepam Ro 5-2925 desmethylmedazepam Ro 5-3059 nitrazepam Ro 5-3350 bromazepam Ro 5-3438 fludiazepam Ro 5-4023 clonazepam Ro 5-4200 flunitrazepam Ro 5-4556 medazepam Ro 5-5345 temazepam Ro 5-6789 oxazepam Ro 5-6901 flurazepam Ro 15-1788 (antagonist) Ro 21-3981 midazolam RU 31158 loprazolam S 1530 nimetazepam SAH 1123 isoquinazepam SAH 47603 temazepam SB 5833 camazepam SCH 12041 halazepam SCH 16134 quazepam U 28774 ketazolam U 31889 alprazolam U 33030 triazolam W4020 prazepam We 352 triflubazam 288 RESEARCH, GENERIC AND TRADE NAMES Research Designation Generic Name We 941 brotizolam Wy 2917 temazepam Wy 3467 diazepam Wy 3498 oxazepam Wy 3917 temazepam Wy 4036 lorazepam Wy 4082 lormetazepam Wy 4426 oxazepam Y 6047
    [Show full text]